Lawmakers hear competing claims on LB1222: expand coverage for Alzheimer's treatments and cognitive rehabilitation
Loading...
Summary
LB1222 would require state-regulated private insurers to match Medicaid coverage for certain Alzheimer's disease-modifying treatments, prohibit step therapy for those drugs, and expand coverage for cognitive rehabilitation after brain injury. Clinical advocates urged timely access; DHHS and insurers warned of potentially large fiscal impacts and loss of step-therapy tools for managing future high-cost drugs.
Senator Jason Prokop introduced LB1222 to require private, state-regulated insurers to provide the same coverage that Nebraska Medicaid currently offers for certain Alzheimer's disease treatments and to prohibit step therapy for those disease-modifying drugs. The bill also would expand coverage for medically necessary cognitive rehabilitation following acquired brain injury.
Clinicians and patient advocates urged the committee to move promptly because early diagnosis and early access to disease-modifying therapies are critical. Dr. Daniel Pierce, a physiatrist and brain-injury specialist, and representatives of the Alzheimer's Association described evidence that cognitive rehabilitation and early treatment improve outcomes and reduce long-term institutional costs. Alex DeGarmo of the Alzheimer's Association said two disease-modifying treatments have received FDA approval and said the bill would ensure parity between Medicaid and private plans.
DHHS deputy director Matthew Ahern and insurer witnesses opposed parts of the bill. DHHS said Medicaid currently covers applicable FDA-approved diagnostics and treatments but cautioned that new drugs in the pipeline could be extraordinarily expensive and that removing step therapy could expose the state to large fiscal liabilities if costly drugs are approved in coming years. Blue Cross and the Nebraska Insurance Federation reiterated opposition to open-ended mandates, arguing many brain-injury rehabilitative services already receive coverage when medically necessary and asking for clearer clinical definitions and limits.
Proponents emphasized long-term savings from rehabilitation and earlier intervention; opponents highlighted uncertainty over future drug approvals and the potential need for safeguards such as clinical registries and monitoring. The committee took testimony from clinicians, advocates, DHHS and insurers and left the record open for further consideration.
